A Phase II Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2015
At a glance
- Drugs MABp1 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors XBiotech
- 07 Jul 2015 Results published in the media release.
- 07 Jul 2015 Results published online in the Journal of Diabetes and its Complications, according to an XBiotech media release.
- 30 Oct 2012 Interim efficacy results reported in a XBiotech media release.